Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | QPCT | Q16769 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11214328 | 0.95 | TBXAS1 (0.44) | CYP2B6TBXAS1CYP19A1HRH3GAA | |
| SCHEMBL15670764 | 0.84 | CYP2B6 (0.57) | CYP2B6TBXAS1CYP19A1HRH3GAA | |
| SCHEMBL5096971 | 0.79 | CYP2B6 (0.54) | CYP2B6TBXAS1CYP19A1 | |
| SCHEMBL5096962 | 0.79 | CYP2B6 (0.54) | CYP2B6TBXAS1CYP19A1 | |
| SCHEMBL18462321 | 0.79 | CYP2B6 (0.54) | CYP2B6TBXAS1CYP19A1 | |
| SCHEMBL6978422 | 0.76 | CYP19A1 (0.46) | CYP2B6TBXAS1CYP19A1HRH3GAA | |
| SCHEMBL11051486 | 0.75 | CYP2B6 (0.68) | CYP2B6TBXAS1CYP19A1HRH3GAA | |
| SCHEMBL11050188 | 0.75 | CYP2B6 (0.68) | CYP2B6TBXAS1CYP19A1HRH3GAA | |
| Iodide SCHEMBL16164357 | 0.73 | CYP2B6 (0.66) | CYP2B6TBXAS1CYP19A1HRH3GAA | |
| SCHEMBL7837812 | 0.73 | HRH3 (0.40) | HRH3QPCTCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1285588-C | Farnesyl protein transferase inhibitors | SCHERING CORP (US) | 2006-11-22 | — | — | CN | disclosed |
| EP-1140904-B1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6800636-B2 | FOR THERAPY OF CANCER | SCHERING CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-20030040520-A1 | Farnesyl protein transferase inhibitors | GUZI TIMOTHY (US) | 2003-02-27 | — | — | US | disclosed |
| CN-1352642-A | Farnesyl protein transferase inhibitors | SCHERING CORP (US) | 2002-06-05 | — | — | CN | disclosed |
| US-6362188-B1 | ANTICANCER AGENTS | SCHERING CORPORATION | 2002-03-26 | — | — | US | disclosed |
| EP-1140904-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037458-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |
| US-4528195-A | Imidazole derivatives and salts thereof, their synthesis and intermediates and pharmaceutical formulations | THOROGOOD PETER B (GB) | 1985-07-09 | — | — | US | disclosed |
| EP-0003560-B1 | IMIDAZOLE DERIVATIVES AND SALTS THEREOF, THEIR SYNTHESIS, AND PHARMACEUTICAL FORMULATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-02 | — | — | EP | disclosed |
| US-4416895-A | ANTICOAGULANTS, ANTISHOCK AGENTS | BURROUGHS WELLCOME CO. (US) | 1983-11-22 | — | — | US | disclosed |
| EP-0003560-A2 | Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040520-A1 | Farnesyl protein transferase inhibitors | FNTA, FNTB, CETP | CYP2B6 3158/4885TBXAS1 810/4885CYP19A1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.